Cloud-clone
SKU:PAB889Mu03
Polyclonal Antibody to Cyclin Dependent Kinase 2 (CDK2)
Polyclonal Antibody to Cyclin Dependent Kinase 2 (CDK2)
Couldn't load pickup availability
Western blotting: 0.2-2µg/mL;1:250-2500
Immunohistochemistry: 5-20µg/mL;1:25-100
Immunocytochemistry: 5-20µg/mL;1:25-100
Optimal working dilutions must be determined by end user.
Product No.
PAB889Mu03
Organism Species
Mus musculus (Mouse).
Source
Polyclonal antibody preparation
Host
Rabbit
Potency
n/a
Ig Type
IgG
Purification
Antigen-specific affinity chromatography followed by Protein A affinity chromatography
Label
None
Immunogen
RPB889Mu03-Recombinant Cyclin Dependent Kinase 2 (CDK2)
Buffer Formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
Traits
Liquid
Concentration
500µg/mL
Organism Species More
Homo sapiens (Human), Rattus norvegicus (Rat)
Applications
WB; IHC; ICC; IP.
If the antibody is used in flow cytometry, please check FCM antibodies.
UOM
20µl 100µl 200µl 1ml 10ml
SPECIFITY
The antibody is a rabbit polyclonal antibody raised against CDK2. It has been selected for its ability to recognize CDK2 in immunohistochemical staining and western blotting.
USAGE
Western blotting: 0.2-2µg/mL;1:250-2500
Immunohistochemistry: 5-20µg/mL;1:25-100
Immunocytochemistry: 5-20µg/mL;1:25-100
Optimal working dilutions must be determined by end user.
STORAGE
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
| Magazine | Citations |
| Leukemia & Lymphoma | The nanoparticulate Quillaja saponin KGI exerts anti-proliferative effects by down-regulation of cell cycle molecules in U937 and HL-60 human leukemia cells Pubmed: 24138332 |
| Future Medicinal Chemistry | Construction of some cytotoxic agents with aurone and furoaurone scaffolds pubmed:29235893 |
| Synthesis of Novel Heterocyclic Compounds Containing Benzothiophene of Expected Anticancer Activity. : |
| Catalog No. | Related products for research use of Mus musculus (Mouse) Organism species | Applications (RESEARCH USE ONLY!) |
| RPB889Mu01 | Recombinant Cyclin Dependent Kinase 2 (CDK2) | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPB889Mu03 | Recombinant Cyclin Dependent Kinase 2 (CDK2) | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPB889Mu02 | Recombinant Cyclin Dependent Kinase 2 (CDK2) | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAB889Mu01 | Polyclonal Antibody to Cyclin Dependent Kinase 2 (CDK2) | WB; IHC; ICC; IP. |
| PAB889Mu02 | Polyclonal Antibody to Cyclin Dependent Kinase 2 (CDK2) | WB; IHC; ICC; IP. |
| PAB889Mu03 | Polyclonal Antibody to Cyclin Dependent Kinase 2 (CDK2) | WB; IHC; ICC; IP. |
| LAB889Mu71 | Biotin-Linked Polyclonal Antibody to Cyclin Dependent Kinase 2 (CDK2) | WB; IHC; ICC. |
Share
